Teva Pharmaceutical Industries Limited (TEVA) Earnings Call Transcript
November 3, 2026
Earnings Call Speaker Segments
Hello, everybody, and welcome to the Q3 2026 Teva Pharmaceutical Industries Earnings Conference Call. My name is Elliot, and I'll be coordinating your call today. [Operator Instructions] I would now like to hand over to Christopher Stevo, Head of Investor Relations. Please go ahead.
Thank you, Eli. Good morning and good afternoon, everyone. Thank you for joining us for our third quarter earnings call. As usual, our materials are posted to our website this morning, so please feel free to see them there. And before I turn the call over to our CEO, Richard Francis, I'd like to remind everyone that we'll be making forward-looking statements on this call. The company cautions that investors that any forward-looking statement involves risks and uncertainties and is not a guarantee of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. These factors are described in our earnings press release and our most recent Forms 10-Q and 10-K filed with the SEC. Any statements that we make are only as of today, and we undertake no obligation to update those statements subsequently. However, I will now undertake the obligation to give you our CEO, Richard Francis.
Thank you, Chris. Good morning, and good afternoon, everybody. Thank you for joining the call. With me talon this call will be Dr. Eric Hughes, Global R&D and Chief Medical Officer and Eliyahu Kalif, CFO. Now moving on to the next slide. as do I start with the pivot growth strategy and the four pillars. We launched in 2023, and I'm going to give you an update in Q3 is the progress we've made against this strategy. Starting with delivering our growth engines. You'll see that the invite portfolio continues to perform well. The set out Jobstl delivering strong Q3 performance and our innovative portfolio is up 33%, and we're raising full year guidance across all of these products. Now the importance of these products can be seen in our financials, and you'll see that our revenue is stronger, our margins and our free cash flow also becomes strong. Now looking to the second pillar, step-up innovation. You see that we have eight major milestone readouts this year, but also we've seen some good progress. And we prove Welte was a significant amount of rent to Teva as well as the patients stopping in schizophrenia. We also have good progress in Ecopia we have FDA fast track designation for our anti IL15 candidate select disease. And so looking ahead, we have four additional potential submissions over the next five years. With regard to an announcement we made earlier in the week are Solman after an independent data monitoring committee met on a prespecified interim futility analysis, we have discontinued the Phase II study. That's got to point out there were no safety concerns. Now while this outcome was not what I hoped for, and I'm deeply disappointed for the patients we are hoping to serve and the position to help us on this journey. I'm particularly proud of the team and the effort we put into this program. What we have learned and will take forward with even more determination. Now another change to our pipeline that happened before the earnings was regard to BioXcel and the acquisition of BXCL501. This is an asset that we think is going to further strengthen our neuroscience franchise and our psychiatric portfolio. There's a big unmet medical need, we believe, in treating agitation at home, and we think this in the hands of Teva could really help these patients with this unmet need. Now moving on to Sustained Generics POWERHOUSE. Biosimilar, as you'll see throughout the presentation of becoming a significant growth drives now at Teva in our genomics business, we have 15 products in the market and 16 more in our pipeline and more opportunities to expand this. And actually, earlier today, you may have seen in the press release, we show we have further strengthen our partnership with Samsung with two FDA pro and TNF alpha biosimilars. On the final pillar on capital allocation, with the latest S&P upgrade, Teva has now achieved an investment-grade status across all three major rating agencies, reflecting the continued strength of our financial profile. We also in this last quarter, we financed $4.9 billion of senior notes. We think about doing that. And then with regard to EDS conversions to ordinary shares in the New York Stock Exchange, we've now opened up the opportunity for broader investment access to Teva. Now starting with what I think was the highlight of Q3 for us, which was the launch of WELTRUZA and the approval of Motus. Now this is a milestone to cover, but more importantly, a milestone on a basket patients living with schizophrenia. Let's be clear, I start with the patient. Schizophrenia is a devastating disease and every relapse can have a significant impact on patients and their families. With WELTRUZA brings a proven olanzapine efficacy in a once-monthly subcutaneous injectable for the opportunity to help patients stay on treatment and reduce relapses. WELTRUZA is the first and only long-acting injectable with no loading dose, no oral supplementation or post-injection monetary. And because of this, we believe Voltus can make a real difference to patients suffer from schizophremia. So what's the opportunity? Well, on the next slide, you can see that significance. With 2.2 million people who are diagnosed with Skip in the U.S., approximately 1.7 million are treated and approximately 20% of the prescription are for all alacrity. We all know that olanzapine has a well-established efficacy and then safety profile, and that is going to through the strong foundation for worse. But also, as we all agree that our commercial organization is very well positioned to succeed with Virtusa building on the great work that has been done over the last three years with used, and I'll go into that in more detail later. But when you combine these two products, we have a portfolio designed to invest a board spectrum of unmet needs with Justin Morteza, highly differentiated and yet complementary. They're anchoring the two proven molecules of risperidone and olanzapine. And because of this, we have confidence in achieving the peak sales of $1.5 billion to $2 billion. But now let's move on to the financials. Now Q3 2026 reflects Teva's transition to a biopharma company. And the factor in the numbers here. So let me walk you through that. So revenues declined 2%. But our gross margin grew to 58.7%. That's up 345 basis points. Our EBITDA grew 7% and our non-GAAP EPS was up 10%. Now I remember way back in 2023 when I presented the first quarter's and our gross margin was approximately 48%. So this really shows the substantial progress we've made in transitioning this company from a pure pay generics to a biopharma company. Now this isn't a one quarter effect. Reflects deliberate choices we have made to transition the business. We set out in 2023 to become a biopharma company, and these results show that the transformation is happening. And what I'd highlight is there is more to come. Now these results include IPR and impact, and Ellie will present and explain in a few minutes. Now moving on to the next slide. Our total revenues of $4.4 billion Innovative was up 33% year-on-year, as I mentioned, sera was up 21% globally at $751 million. The study was up 96% at $85 million, and GP was up 61% at $269 million. generics were down 16%, and this was largely due to the low contribution of generic revenue. But now let me go into a bit more detail. So on to Astera. Astella reached a $2.5 billion target one year ahead of schedule. Really, really proud of this, and congratulations to making this happen. So revenues in the U.S. were up to $727 million, up 21%, and the fundamentals remain strong. U.S. TRx grew 18% and milligram dispense grew 23%. Now given this strong momentum, we increased our outlook by $75 million at the midpoint, so I said will now be $2.55 billion to $2.65 billion. So congratulations to them on that. I would like to highlight that the opportunity for better remains strong. You see that the market growth content remain new patients with 85% of patients not treated, we see a strong opportunity to keep growing this product to greater than $2 billion of Poetas we previously communicated. Now moving on to say. The study is the poses growing oreoschizophrenia. Revenues grew 96% to $85 million in Q3, and the underlying demand remained strong with Terex IT up 62% year-over-year. Now the excellent commercial execution is expanding the market. you steady nearly doubling with burden LAI share from 5% to 10% and capturing approximately 83% of Risperdal LAI. It is worth noting that if you remember back to 2025 Q3 and Q4, we did have some one-off negative impacts were keeping that in mind when we plan forward. That said, we increased our outlook on used by GBP 20 million at the midpoint, another range of $290 million to $310 million. It probably doesn't need pointed out, but I will that this continued excellent execution gives us a solid foundation on which Donatos. Now moving on to AJOVY, continues to expand its global leadership in migraine, continue to outperform the injectable market and lead in many markets where we have launched. Global revenue reached $269 million, up 61% year-over-year with strong momentum across many markets. In the U.S., revenue grew 89%, while ex U.S. momentum remains strong, supported by volume growth as well as market share gain. Because it is strong momentum. We will increase our outlook by GBP 85 million at the midpoint, so raising it to $930 million to $960 million. Now I'd like to point out this doesn't happen by chance. And if you remember, when we started on journey in 2023, he was talking about a Josie reinvigorated it. And I think this reflects something broader that et cetera. We do things with intent and we execute with intensity. And that's why looking beyond 2026, we see a path to greater than $1 billion of pales good. Now moving on to a couple of new products in our pipeline that I touched upon earlier. Firstly, ECoPipeline. This is a first-in-class opportunity for Traton combining compelling efficacy and favorable tolerability in a seriastic pediatric neurological disorder with limited treatment options. There are 100,000 pediatric patients who live with toutsyndrome would be 50,000 are treated but unfortunately, only 20% to 30% remain on therapy after one year. We hope to help that and help to help these patients in each children. Our next key milestone is obtaining regulatory approval, which we anticipate in Q1 2027. Now moving on to the latest addition to our innovative pipeline with the assets that we acquired from Box, which is BXCL501. This is expected to address another clear unmet need for patients experience acute agitation of home, extending our patient focus in neuroscience and bringing potential benefits to nearly 7 million patients. The XTR 501 could be the first at-home fomenfor acute agitation and in regulatory approval, adding another different opportunity and significant value to our neuroscience portfolio. This order also highlights another example of disciplined capital allocation, funding different assets, whichever and have real value. Now my colleagues will go into more detail on capital and BXCL501 next week at our R&D Day. Now moving on to the next slide. When we talk about growth and we talked about the impressive growth in Q3, it's worth pointing out that we have a decade long runway of growth catalysts. And as you can see here, we have a maturing pipeline that I will talk about in more detail next week. We actually look at 2030 beyond, it really does get quite suggested this slide, and that is a very exciting opportunity for Ceban for potential investors. Now moving on to the next slide, a slide which we've talked about in the last couple of years. But now we see starting to see some of these products actually come to the market. Obviously, we've spoken about Virtusa. We've spoken about the near-term opportunity in Q1 for Ecopipedown. Now we've added BXCL501. So we have a pipeline here that we are confident to deliver over $10 billion of sales tevagoing forward. But we'll give more detail on this at our R&D day. Now moving on to the generics business. Now to not powerhouse we're going to have is resilient beyond Revlimid, which is exciting. And let me share the fundamentals that drove this. If you take away generic Revlimid, Global Generics business grew 1%, with the U.S. down 3% and EU up 7%; in emerging markets, down 4%. Now we expect our generics business to be flat to slightly up in 2026 and but we continue to be positive about the long-term growth trajectory of this business, 1% to 2% over the long term. Now I remain very optimistic about the future of our generics business and the main reason the growth rate is really around our roughly expanding by portfolio pipeline. So now if I move on to that, we see this clearly on this -- it's one of the fastest-growing biosimilar businesses we have there. We set out to achieve $800 million of sales by 2027. Well, and I'm in a position to tell you today that we're going to do that in 2026, a year ahead of schedule. And at the same time, we're expanding our portfolio from nine assets in 2024 to 15 today and potentially 18 in 2027. But it's worth noting this is not simply about adding assets. We are deliberately shifting our portfolio towards biosimilars and increasing important growth driver for our genomics business. And what's important, it's not just about the portfolio. It's how we execute it. And as you can see, 3 out of the 5 U.S. Bisnis right #1, while in Europe, we are building a leading positions across several important markets. On to the next slide. We're going to continue on this journey, expanding our portfolio and bringing these biosims the markets in both the U.S. and Europe. And as you can see here, we have the potential to be 31+ already, but I've also realized that this slide is already out of date. Because of the deal we announced today with Samsung, so it should be 32. So apologies for that, but it does really reflect the speed we move out at Teva. So based on this the solid foundation of innovation and the portfolio transition of generics business with biosimilars. I can move on to the next slide. We say we are firmly on track to achieve our 2027 targets that we laid out back in 2023. And with that, I'm going to hand over to Eric.
Thank you, Richard. We're going to have my first slide. I just want to review really quickly the progression of our innovative growth drivers. This is led by a trio of neuroscience products for the approval of well-run and now the hopeful approval in 2027 of ecopyptane for Tres disease. And then finally, our new drug dexmedetomidine that is being used for the treatment of agitation we're looking for a PDUFA date in Q4 of this year. So really a great spearhead leading with our neuroscience portfolio. But following on to that is our burgeoning innovative pipeline in immunology, moving off with Day, which will be ending our Phase III study soon with our last exacerbation hopefully around the end of this year. We're also progressing Dovato. It's obviously in Phase III at this point but also price Syncona's disease, but we'll also be initiating hydrogenate Supertea and proposimatic Crohn's disease with our partner Sanofi. And then finally, our IL-15 program, we have exciting new data this year in our proof-of-concept study in Vitiligo and Citi disease. So a real engine of growth for our innovative drivers. On the next slide, though, the Rio fell of the ball today is well chosen. This is a fantastic product for patients with schizophrenia, building upon the known efficacy of elonzapine, but we really delivered on the label with no loading dose, no oral supplementation and no post-injection mono. I just have to give a shout out to the R&D team for doing such a great job in his development. And I appreciate that our data set was so well received by the FDA to give a label that really gives something that patients can use in the future. So two risks to the team. But on the next slide, I just want to really go, there's been a lot of momentum just since the last earnings call in Q2. Since then, we have the announcement of the priority review at ecopitan. We had the submission of the IND for the hydrogenated Supertea study and for dupatetub. We announced and shared some top line data that showed clinically significant changes in our gluten challenge for Signal disease. We have presented our Virgo data at the EADB conference in September. We achieved the futility analysis for Emerson. Unfortunately, that didn't turn out the way we wanted. Team did a great job in executing the study, and we'll review the worlds of data that we've produced to see how we're bringing that program forward in the future. But really, the luxuries was a big announcement on October 8. And then finally, we presented at UEGW due to keep to data on the maintenance data, how we started the entire year, bring it full serve on presenting that great data for duties. So lots of momentum just in the last quarter. So we're very proud of that work. And if I could go to the next slide. So you can see we're marching down the catalyst that we had outlined at the very beginning of the year, VTech an IL-15 Day Emerson. Now we're adding Weltreza, and we'll be talking about PD-12 and dexmedetomidine in the future R&D meeting next week. And finally, I'm just going to end with the fact that I was going to be quick today because we'll be talking a lot more about some deep dives into our pipeline, some new programs and new data that we'll present next week on November 11 at our R&D Day. I hope people can call in and listen to the webcast if you need more details, just visit our website or write to us. And with that, I'm going to pass it off to Elie. .
Thank you, Eric, and good morning and good afternoon to everyone. I would like to start my review of Q3 '26 results with the following key messages: first, sustaining innovative growth momentum. We expect it to continue to deliver strong product mix growth supported by disciplined commercial execution and focused investment while transforming to a high-margin profile. Second, continue to maintain credible test to 30% operating margin by 2027, capture the full benefit of the transformation program, including structural cost savings, productivity improvements, and operating leverage from a more favorable growth and product mix while actively mitigating generic revalued earning erosion. And lastly, execute a disciplined capital allocation strategy. Preserve financial flexibility, while prioritizing debt reduction and sustained execution on our financial policies, resulting in investment-grade profile. Targeted business development investment with acceleration of innovative R&D and focus on shareholder return. Now starting with our Q3 GAAP performance on Slide 30. Before I discuss our Q3 results, let me briefly explain why we also reflected the IP R&D impact. IP R&D can result in a significant upfront and milestone expenses related to investments and externally acquired or licensed pipeline assets. Given this transaction-driven nature of these expenses, starting with Q3 26 represent the impact of this transaction on our results to provide a clearer and more comparable view of our underlying operating performance. Q3 revenue were approximately $4.4 billion, down 2% in U.S. dollars and in local currency compared to Q3 '25. This decrease was largely driven by lower generics products, many general revenue and was largely offset by continued strong growth of our key innovative products, Steel, Ajei and Zed. GAAP net profit and profit per share were $273 million and $0.20, respectively. Turning now to our non-GAAP performance. Our non-GAAP gross margin in Q3 '26 was 58.7%, an increase of 345 basis points, reflecting a favorable mix of products with strong growth in our key innovative products, partially offset by lower revenue from generics products, mainly generic revenue. and GAAP operating margin was 31.7% to 182 basis points above Q3 last year. This increase in operating margin was mainly due to a higher gross margin partially offset by higher planned investments in sales and marketing to support our innovative growth and launch preparation for Witsawell as by capital gain from the sale of property in Europe. Overall, we ended the quarter with a non-GAAP EPS of $0.86, 10% higher compared to Q3 '25. Our free cash flow in Q3 was in line with our expectations at $495 million slightly below last year. In October 26, we repaid approximately $1.8 billion of our debt maturity. As of today, no amounts are outstanding under our revolving credit facility. To provide you with some additional color our Q3 '25 year-to-date results included approximately $1 billion revenue and $730 million EBITDA contribution from our gnlrevenue. Our Q3 '25 results included $430 million revenue and $300 million EBITDA contribution from generics ovens. Excluding these, our financial results year-to-date and for this quarter reflects a strong underlying performance. Moving to the next slide. As a reminder, our operating margin expansion to 30% is driven by two structural elements. The first is a portfolio shift towards higher growth higher-margin innovative products; and second are the Teva transformation program. We continue to make solid process with our day-to-day operating margin, reaching 28% on our updated 2026 guidance of 27.8% to 28.2%, all excluding for IP R&D expenses. Looking ahead to 2027, we expect a further 180 to 220 basis points of improvement, driven by the full expected impact of our transformation program and continued innovative growth while compensating for generic submit erosion. This is the core of our financial transformation, moving from the company historically driven by generics to a bar from a company. Moving to Slide 32. I Focused financial management has been an important source of cash creation for us. And importantly, it has allowed us to redirect capital towards high-return opportunities. From 2022 through 2026 improvements in net working capital generated approximately $1.3 billion of incremental cash with additional approximately $160 million from lower interest expenses Together, that represents roughly $1.5 billion of cash generation that we have been able to redeploy into the business, including accelerating our innovative pipeline and investing in our broader priorities. Looking forward, we see the opportunity to continue these dynamics between 2027 to 2030, we expect to generate an additional of approximately $500 million to $900 million from net working capital together with approximately $1.4 billion to $1.6 billion from interest expense savings, bringing the cumulative opportunity to approximately $3.4 billion to $4 billion. By the end of 2030, we expect to reach negative net working capital as a percentage of revenue. And importantly, as the business grows, this becomes increasingly powerful we are freeing up capital and reinvesting it in higher rates of return, while continuing to grow and create further capacity for investments. At the same time, we remain focused on maintaining the right balance sheet. We have repaid approximately $12 billion of debt since 2019 and remain on clear as for the net debt to EBITDA to time by the end of 2027. With approximately $2.7 billion expected free cash flow in 2027 compared with less than $1 billion of annual maturities from 2028 to 2030 and approximately $2.5 billion of free cash flow expected in 2030, we believe we have a significant financial flexibility to continue investing in our growth while maintaining appropriate leverage. So this is really a reinforcing cycle. Disciplined financial management generates cash. That cash is reinvested into a higher return to growth opportunity and then the business growth we create even greater capacity to invest. Now turning to 2026 outlook on Slide 33. Based on our strong performance year-to-date, and the visibility into the remainder of the year, we are raising our full year revenue guidance range to $16.7 billion to $17 billion, which is an increase of $175 million to our midpoint. We're also updating our outlook range for operating profit, adjusted EBITDA, EPS and free cash flow. As Richard mentioned earlier, the acquisition of DXC 501 from BioXcel is now closed. Further reminder of the deal terms. The agreement provides for $57.5 million upfront payment as well, up to $67.5 million in potential contingent payments linked to the timing of expected FDA approval and certain sales milestones. Let me provide some color on our guidance assumptions, starting with the revenue. First, our innovative portfolio continued to perform strongly across all three products, offer, Ajovy and Use. We are increasing the full year guidance for all the three products with asset now expected $2.55 billion to $2.65 billion, a job at $930 million to $960 million and user at $290 million to $310 million. We expected our global generics revenue full year to be flat to slightly up in local currency compared to 15%, excluding the impact of generic Revenue and the divested Japan business. We continue to expect 2026 non-GAAP gross margin to be in the range of 54.5% to 55.5%. We now expect 2026 operating income to be in the range of $3.8 billion to $2.9 billion, with an operating margin of 22.6% to 23.1%. Excluding IP R&D, this range will be between 27.8% to 28.2%. Our operating expenses continue to reflect the deliberate investments we are making to support our growing innovative portfolio and biosimilars. Our guidance for operating income and adjusted EBITDA reflects this continued growth investment in OpEx, with adjusted EBITDA now expected to be in the range of $4.23 billion to $4.42 billion. Excluding IP R&D, this range will be between $5.1 billion to $5.3 billion. We continue to expect finance expenses to approximately $800 million and a tax rate in the range of 20% to 23%. Our diluted EPS guidance is now $1.92 to $2.11, and we are also increasing our guidance for free cash flow to be in the range of $2.1 billion to $2.4 billion for the full year. Now let me provide you some additional thoughts on Q4. For set, we continue to expect revenue in Q4 2026 to be down year-over-year, due to expected expense exchanges in the purchasing patterns and the pricing environment ahead of the IRA implementation in January. In addition, we are preparing for the Q4 launch of Citrus. Since the initial volume is expected to be large sample of vouchers as we establish the payer coverage, we continue to expect no major revenue contribution in Q4. Over the last several years, we have consistently delivered on our commitments and made significant progress across our key financial metrics. Today, we are not providing detailed 2027 guidance outlook, but looking ahead, we expect this momentum to continue with a mid-single-digit growth on revenue CAGR from '23, '27. We outlined on Slide 69, more comprehensive information about our financial trajectory. Moving to the next slide on capital allocation. Over the last few years, we have made significant progress in strengthening our balance sheet. This progress allow us the financial flexibility to invest in our innovative portfolio and pipeline evaluating value-accretive business development opportunities, along with the optionality of returning capital to shareholders through buybacks when appropriate. And lastly, I would like to briefly touch on our transition to a direct ordinary share listing on the New York Stock Exchange. We believe this change is making Teva shares more traceable to a broader investor base. who are now able to buy ordinary shares directly in a serious manner and strengthening our position in the U.S. capital market. Together with our recent return to investment grade credit ratings from all three major rating agencies, this represents another important milestone in our financial transformation. We believe this transition reflects the momentum we are building through our pivotal growth strategy and further enhance our ability to invest for long-term growth and create shareholder value. With that, I will now hand it back to Richard for his closing remarks.
Thank you, Ali. So in summary, Teva is now a more focused high growth by a pharma company and our Pivot code strategy is delivering. The growth engine of our innovative portfolio is accelerating state, SEDI and Adobe are growth drivers, and we're excited by the recent FDA approval of Weltoza. In the near future, our incremental growth will come from the next generation of innovation. And to conclude on the next slide, as we continue our journey, three themes are clear. In a pivotal year for TAVR, we delivered as promised. Our pipeline is advancing with speed. Our disciplined capital allocation is what sets us apart. And to build on what Eric said, we are looking forward to seeing you at our R&D Day next week in New York City. With that, I'll open the floor to questions. Thank you. If you would like to ask a question.
Sorry, Ali, before you get ready. I just wanted to remind people if you just try to limit yourself to one question and one follow-up. And if you have additional questions, we're happy to have you back in the queue and we'll answer his many a time for me. Sorry, go ahead, Elie.
[Operator Instructions] Our first question today comes from Jim Choi with Evercore ISI. Please go ahead.
I wanted to touch up on 2 things here. First, the last slide has this interesting disclosure on a possible 57% to 58% gross margin in 2027 and I believe that's a new disclosure, which is up quite nicely from the full year 2026 of about 55% gross margin. My question is this, if Osteo is flattish next year because of IRA implementation -- can you speak to what enables that 200 bps to 300 bps in gross margin expansion, which is presumably not branded business driven? Second, speaking of Astea more specifically, I just wanted to run some math with you. First, -- we heard Gilead mention about $1.5 billion in IRA impact of Biktarvy, which represents something between 1/4 to 1/3 of Biktarvy's Medicare exposure. So considering Osteto's Medicare exposure is about $1.5 billion, is it reasonable to assume something like $0.5 billion or so in IRA exposure for AUSTEDO into next year?
Thanks for the question. And I appreciate the fact that you look through all of the slides in the appendix. Thank you for that. So I'll hand over to Eli to talk a bit about the gross margin. But I think one thing I'd say on a high level is when we did disclose the direction of travel with our gross margin back at our Capital Markets Day, I think what you're seeing is the fact that the transition to a biopharma company is accelerating that because our portfolio is transitioning presenter scale combined with some of our efficiency trials. But I'll hand that to Elie to give you a bit more context.
Thank you, Omar, for the question. We did mention in the past that 57% to 58%. And while keeping the 27%, 28% OpEx get us to the 30% OP, but that's just kind of the high level. But what I will mention is the following. If you look on just this quarter, we see able to be above 58% compared to last year, the same quarter was a bit above this 55%. This is kind of a 350 basis points and mainly coming from the innovative shift that we have on our revenue mix. What we want to see next year, and to remind everybody, we have the $700 million on consumer on saving, around 2/3 of it is actually related to OpEx, and we are going to actually utilize it noogizing this year, but the rest of the program is more kind of a backlog-related to our network optimization, which is going to impact our cost. So if you think about us ending the year close to, I would say, in the high range of 55.5%. You get 200 basis points at the midpoint of the 57%, 58%, onto 100 basis points going to manufacturing and optimization of our costs and 100 basis points on to our innovative revenue shift.
And look, one thing I'd say about trajectory gross margin upwards, it will just keep continuing. It's just a question of by how much, but it will continue because of the transformation of our portfolio because of the transformation and the launches we have coming up. Now to answer your second question, Umer. Generally speaking, yes, you're right. So that's probably the first thing to say. Without getting into guidance, consistent with our past practices, we will provide guidance in '27 next year. But yes, we have a high degree of confidence that instead of will achieve $2.5 billion next year and greater than $3 billion of peak. 2027 was always a year we planned for. We have strong fundamentals offsetting the IRA impact. And so that's what gives us the confidence in that. I'd say, just to give any more broader context, what's really changed is the company is having a portfolio of vibrant addition to setter. So once again, not given guidance in 2027, we expect Teva's revenues to grow again. Besides used gene were now adding Motus any good Pipa and then potentially make the XL 501. So our portfolio of innovation allows us to continue to grow beyond '27 -- in '27 and beyond, and that allows us to grow our margins. So I think it's a good question. I appreciate you also because it's multi-let it fundamentally comes back with the execution of the pivot-to-growth strategy, the execution of leaving us to a biopharma company with a fast-growing innovative portfolio. Thanks for the question.
We now turn to Douglas with HC Wainwright.
Maybe two questions on AUSTEDO and AJOVY. First, in terms of Osteo, I noticed you've continued to have an acceleration in terms of the milligrams per patient. And I'm just curious, some of that is obviously just coming from natural migration to X -- but I'm curious, within the XR franchise alone, sort of how much continued traction have you had I know you're not -- patients are generally not getting to the 36.6% that was in the Phase III trial? And how much of a focus is it to sort of get patients ultimately to that level? And then just in terms of AJOVY, where we've sort of had the franchise really renewed growth recently. I'm just curious when you think about the prospects what you're necessarily seeing in the U.S., it looks like you're doing better on a revenue standpoint per patient, sort of how you see share shaking out you've definitely taken share from Aimovig over the long term and how much growth will come from U.S. versus ex U.S?
Okay. Firstly, thank you. I think it's the right word for the coverage. So I appreciate that. And thank you for your questions. So let me try and pick them off. So firstly, I'm going to start with state. So you talked about the milligrams growth there, 22%, Q3. I don't mean sort of how that has happened is a couple of things. Firstly, there was the launch of XR, but then there was also the launch of the ability to get a titration pack through prescription because one of the things about Astellas you need to say trade up to the optimal dose, to get efficacy. So having a titration pack prescribed and then having XR once a day just makes that process simpler. And so that's what we really. We haven't actively going to drive conversion from for we've let the physician make that choice. So but because of the fact that those two things are in place, we've seen that continuously improve, which is good for the patients because we want to have the patients on the most efficacious dose. And one of the challenges and opportunities with the state is that people start to feel letracy pretty quickly, but we want to make sure they go out to something that is most optimal for them, but that's a position to use the titration pack and exon do that. So that's the fundamental of that, and we see continued good progression of that this year and going forward. Now on to your question around JV, I think, was around about the U.S. performance and how strong that is and then the rest of the world performance. So let me sort of talk you through the U.S. performance first. CS performance and it goes back to what I said in my opening remarks, this is about a focused execution on delivering a strategy at a brand level. What do we want to do globally and what do we want to do locally and what capabilities do we need to put around what resources and what choices do we need to make. And I think in the U.S., we've seen the work with the team and make decisions on making sure we have the right access and the right value. And when you do that as well as the growing market share, then we have the ability to disconnected. Then with regard to the rest of the world, you have the opportunity. And as you've seen that we continue to grow in Europe and international markets and above market, significantly above market. And because of that and growing market share. And so if we do that, we continue to see the revenue growth. I think what this highlights because I know this is an unusual situation, but we focus capability and the right resources and the right ambition expectations, we can vitalize a brand. And I think we've seen that with the job. And so that's why we remain confident that we're going to exceed $1 billion in peak sales, which sounds obviously like a big number, particularly when we started our conversations maybe four years ago. Hope I answered your questions.
We now turn to Glenn and with Barclays. Your line is open. Please go ahead.
Richard, just two things I wanted to hit on quickly. when you talked about sort of the biosimilar launch slide, you sort of commented how congested it's becoming. But as I'm sure you're aware, you've seen a bunch of incremental litigation in the space, for example, Janssen seeking a PI on SIMPONI and Genentech bringing a suit on XOLAIR and a lot of concern around ENTYVIO and the launch timing there just sort of given the IP at Takeda. And I'm just kind of curious how Teva thinks about navigating all that potential litigation making the decision on whether to launch these products because on that slide, it seems like you have some incremental contribution coming in '27 from these drugs. And then secondly, I did want to ask about '27 related to Eco-Pan and BXCL501. I'm sure you're going to touch on this at the R&D Day next week, but I'm just kind of curious at a high level, are you expecting any type of reasonable contribution from those two drugs in the second half of '27. And I'll stop there.
Dan, thanks for the questions. So on the biosimilars one with regard to litigation. Yes, that's pretty much the business we're in when it comes to genetician biosimilars, as you know. We want to bring these products to the market and people want to mitigate and stop us doing that. So it's sort of it's not a surprise to us. Obviously, we would like that not being in place, but we strategically plan and we financially plan with realism. So when we think about our portfolio of 32, we take into account the puts and takes. And I think when I started on this journey, high set to people who ask me which is going to be the most successful biosimilar so I don't know because there's too many variables, IP litigation, launch timing, amount of competitors, price erosion, et cetera. But when you have a portfolio you become -- you allow yourself to manage those risks in a more thoughtful way that allow you to continue to grow. And because of that, I feel very confident of the direction we're on with our biosimilar business. I think what's important noting now, we are reaching a certain momentum in scale that this is going to fundamentally change the portfolio of our generics business. And I think that's something for people to maybe double click and recognize. So I think that's one. The other thing I'd say on a biosimilar business is, to some degree, doesn't follow all the traditional rules. As I said, 3 out of 5 of our Biocenters in the U.S. are #1, we were not #1 to the market. So that just shows you it's not as straightforward as people think, and I like that. And the same in Europe. We've come to Europe late in many instances, but we're also showing that we can be #1 in those markets because of the capability and the infrastructure we have in place. So I think biosimilar you'll hear us talking more about what we're going to keep expand that portfolio, and litigation will come and we'll deal with that as and when it comes, but it won't do rareness. Now on Ecopia and BCXL 501 Look, I've got to ensure you turn up next week, so I can't tell you anything. All I'd say it's a good question and the right question. And we'll start to give you some insight into why we're excited about these two products. where we'll give you any guidance on that? You have to wait and see, but I'm glad you're starting to focus on those because I think in our hands, as we've shown, we can really drive value. We just had that conversation on -- but I think when you look at pipeline with a significant unmet need and you look at the BCXL501 with a significant unmet even agitation. I think we're very excited about what we could do with those. So apologies, but I see you in York next week.
Our next question comes from David Amsellem with Piper Sandler.
So actually, you have a couple of ecopipane questions, more longer-term focus. So you didn't provide peak sales potential for the product. And your slide, unlike other products in the pipeline or recently approved. So maybe just a question on how you're thinking qualitatively about how impactful this product could be? How are you thinking about access dynamics, mix of Medicaid versus commercial? And how long do you think it's going to take to get good access any pricing analogs that you can help us with in terms of how to think about that? And then do you think this is a product that could slot in ahead of the approved antipsychotics that are commonly used. I know that's a bunch, but it's obviously an important driver going forward.
Thanks, David. Thanks for the question. No, it's a really good question, and I'll Vericast we'll talk about that third line moving ahead of antipsychotics. But I think you've touched upon on all the variables there that we're thinking about. So First off, there is the fact that we've got to think about what is the appropriate price for such an innovative product that's going to bring companion efficacy and good tolerability and safety. And we did a lot of work on that now because obviously, that is a very important factor in this equation. And so that's another reason why we don't want to talking about sales and peak sales because we want to get that work done, and we want to make sure that as though as it can be. So as we've said in the past, the pricing will reflect something on the air autumn nature where there's a significant unmet need in the pediatric population. The second thing that comes down to then is access and how do we want to approach access. And now, as you know, we are very thoughtful about access and we think about the long-term value of the product and how you have to be thought in what you do with regard to access around that. And so we're working through that. With regard to the medicating and commercial, the mix is a bit different here. So I think we're looking at more commercial plans on this product, which, as I stated in the past is a change for us because we spend a lot of our time doing in Medicaid and Medicare. So I think that's how I would think about it. But I'll hand over to Derek, but what I would say is when I get to speak to physicians and when I actually has spent to patients, and I've actually even come across some people suffer from to that. Then there is a clear opportunity for an efficacious and safe and well-tolerated product to move ahead of antipsychotic. But maybe I'll hand that to Dr. Eric.
Thank you, Richard. So I think that the value of a capitan comes down to the data sets that we've generated to date. There's two well-controlled studies, both in the Phase II and Phase III now, a one with a 30% reduction in the tick experience for the patients and a 50% reduction in the relapse rate. So great data, but more importantly, the site profile was favorable, I think, where you saw very good tolerability in metabolic effects, good activity for their ticks and no abnormal movement disperse. So when I think about how physicians might use this in the future, sure they might step through what they do today with alpha generic receptor agonist, which is off label, then they might go on antipsychotics. But I think when they get used to what the profile is, of equal pipeline? And I guess the -- understand the -- both the efficacy and the safety profile, it will move up in that list of the possibilities out there. I think that, that long-term efficacy, remember, only that mid-20s to people stay on their therapies today. And our long-term follow-up, 66% of the patients staying on the drug for at a year. So I think the profile ones get used to it. Will move up in that format.
Thanks, Eric. Thanks for the question, David.
Our next question comes from Jason Gerberry with Bank of America. .
So one question for Eric. Just what does the time line look like for Teva's efforts to advance a TL1A bispecific into the clinic? I know you guys have some efforts that had been ongoing preclinically. So anything you can update there in terms of time line? And then my follow-up question is just, does the U.S. government agreement exclude Teva from some of the generic tariff headline proposals or I don't know what to call it exactly, but does the agreement provide exemption from any generic tariff risk.
So I can start to answer the question on the T1 bispecifics. So I'll disappoint you after that. I'm not going to tell you much because we have an R&D day next week. And we may be talking about bispecific programs with our TLA. And I would mention that we are one of the first in the TL1A space. We have a very potent Tito selective drug with well antibody antidrug antibodies in full Phase III. But I think that our scientists are the experts in CNA. We'll hear more about that next week.
Jason, with regard to your question on generics, and on the agreement with the U.S. government, as they laid out I think some time ago, it's a two-year time frame, they've put in place to come to some sort of agreement, and so there's nothing that's been concluded there. But as you can imagine, a company like Teva is always at the table. And so as and when we get more information, we'll let you know.
We now turn to Louise Chen with Scotiabank.
Congratulations on the quarter. I wanted to ask you first, what's your latest thinking on M&A and business development. And then secondly, if you could talk about your R&D philosophy a little bit more in the efficiency, which you move products to your pipeline?
Luis, thanks for the question. So M&A. So what we think about is efficient deployment of capital for the time and obviously, we're thinking about that a lot, and we have been thinking that in the last few years, despite that people thinking today wasn't going to come. And what I mean by today is another improving balance sheet, investment grade. And as Elias pointed out, an opportunity for the company to really generate some free cash. And so obviously, we know our balance sheet is going to start to improve significantly. Because of that, we were always planning for this day. I hope you are something that people start to realize. We do plan long term for ever, we start to think about what can be around the corner. And so yes, we do think about more business development deals we think about potentially but it has to be one that we feel that is good value. It drives the long-term value of the company, puts us on a sustainable footing to become a world-class biopharma company. And I think hopefully, you've seen with the deals we've done we're very thoughtful about how we deploy capital externally and making sure we do things that we know will drive good accretion short term as well as long term. And so that's our philosophy. The balance sheet gives us a bit more flexibility, but our discipline will not change. Now on the R&D plastic, you get Salomao. I'm not to give them a headline -- so yes, thanks for the question.
I think it's a pretty simple strategy and philosophy we have. We'll talk about it more next week, but it's really about using known science to increase your POS speed and execution at the weather not AI and its disciplined capital and using partnerships where you can increase your bandwidth and your funding. So it's straight up simple, but you have to execute it.
Thank you for the question. Next question.
We now turn to Dennis Ding with Jefferies. Please go ahead.
Two questions, if I may. One on Voltus. So you frame the market as 2 million in the U.S. diagnosed and 20% on oral olanzapine. So you're essentially implying the TAM is around 400,000. But how does the TAM change given many patients don't tolerate olanzapine because of weight gain and then they eventually discontinue? And while Trust likely we'll have a similar side effect profile. So where do you see well Trusa being realistically used? And I guess in a way, I'm asking if you have an estimate for how many patients have shown efficacy on olanzapine, tolerate the weight gain but are also showing evidence of noncompliance. So that's question number one. And then question number two, for biosimilars. Can you please clarify again and confirm on Slide 20 that you're looking to launch a biosimilar Symphony in the U.S. in 2027. And I'm just wondering because how are you thinking about the litigation aspect here as a barrier for a U.S. launch? And the reason we ask is because the four-day bench trial that J&J has against Biothera starts March 2028. And I'm assuming your partners Benson will be scheduled around the same time frame. So just help me reconcile the timing differences here? And if what you're implying is that you'll be aggressive in pursuing a settlement to ensure 2027 U.S. biosimilar Symphony launch?
Okay. Thanks, Dan. Thanks for the question. So I will face the first one with Eric. But the way that we think about it is -- the reason why olanzapine commands such a large portion of the market in schizophrenia is because it is very efficacious and is seen as the gold standard when it comes to efficacy. So while you've identified some of the metabolic challenges it has when it comes to managing schizophrenia when patients have evischizoplenia, efficacy is the #1 priority. And that's why olanzapine has maintained that segment of the market. So obviously, when it comes to sophisticated compliance becomes key and that's why we think more choose comes in. So in a way, we're not dealing with that the side effects, they're already known and people are picking a lane because the efficacy both the physician and the patient. But I'll let Eric give more context to that.
Yes, I'll add a little bit on the color of that. Well, Thus, its value is it's known efficacy and its known safety profile. So as a hysician, you're using something but bringing something new to it with the LAI. So market approximately already uses alone. That's how well known it is and how use they are of using it. So bringing that convenience and that hopefully added benefit of lower relapses and better adherence within LAI is really the value proposition here. I think that's really defined it very easily for a physician to choose who should get it. And I'd add that we've done the same thing with and a coated space of risperidone here we're launching into a market for LAIs that really has no viable alternative at this point.
Thank you, Eric. And then when you go on to the question that you had on the biosimilar Symphony, when we talk about launch readiness, we talk about the ability to be able to launch. We may not launch and that depends on a number of factors. But we always set ourselves up that we are in a position to launch if possible. And so that's the way to think about it. And obviously, IP litigation can go in many different ways. But what I always insist upon is we are ready, so things do go the way we find them or we hope that they do, and we are there to make sure this access is made available to patients.
Our next question comes from Dan Clark with Leerink Partners.
Wanted to ask my first question on the Offset slide. You mentioned there are new capabilities in place to support MFP effectuation next year. Can you just give some color on what those are and sort of how those might impact either sales or kind of price next year? And then my second question, just a little more clarity on how you're thinking about the timing of Weltzer revenue next year. Should we think about that being more year as you work to secure access? Or any color you could provide there would be very helpful.
Thanks, Dan. Thanks for the question. So starting in reverse order. Onwards, revenue expectations are in the latter half of the year. Let me explain a bit why. So we've launched in this quarter, and this is all about making sure we get access and familiarity with the product both in the hospital forms and with the physicians. Now as you may be aware that we have the majority of our patients in Medicaid and Medicare. And so to get access to batteries, we have to get access on Medicaid for Marisa. And that is something which is limited by each plant. And so some -- we'll do that at launch and some will do that six months, nine months, 12 months. At 12 months, we'll have about 85% of Medicaid coverage. So access is one of the big, very limiting factors and Obviously, then we have Medicare, but it's really Medicaid. Now the things we do on the inputs to make that happen is we have sampling, and we have hospital forms to make sure the hospital formers have it on. But ultimately, it comes down to that. That means you're not going to see revenue of any particular value in the first half of next year. But as a lot of those states come on board, then we see the opportunity to positions to start using volts more broadly. So that's why we say the second half of next year. And obviously, that changes significantly for the full year in 2028. But that's how I think about it. What we will do is make sure we update you all on some of things I call the input or the leading metrics around TRx, around excess breadth of use by physicians, debt of use by physicians. But we feel very confident in where we're having more trust because of the things that Eric has mentioned around the product profile, the unmet medical need. On the fact that we have a really strong capability with used. And then on ASTEDA,I think the question was around what capabilities have we bought to minimize the impact of the IA and the fluctuation of that. It's really doing a bit more of the same. And that we've been planning for this for some time. So we're not certainly walking into 2027 unprepare we've been preparing this for multiple years, as we said, on the primate growth strategy in 2027. We knew this was going to happen or '23, '27. We knew this was going to happen. So we've been building capability putting our strategy around this. So I think we're well placed. That goes down to many factors around how we manage the patients, how we manage specialty pharmacy, how we manage access and we manage multiple parts of the patient journey. And those are put in place some time ago. And so that gives us a level of confidence that we can keep growing this product to over $3 billion in time. And so '27 is just really a stage on the gene to that. And as I repeat, we always plan for 2027. And so in no way we are daunted by the challenges out of us.
We now on to Joseph Thome with TD Securities.
Maybe one on the commercial side first. Just as you're seeing about the LAIs, obviously, one of the benefits can be time on therapy and increased compliance. What are you seeing in terms of real-world used refill rates, any kind of patient time on therapy. And has that matched your kind of expectations ahead of launch? And then maybe one on the pipeline. We've seen a few Celiac data sets this year, how is Teva balancing kind of speed to market versus competition? And also signing off perfectly with the FDA on what endpoints they want in clinical trial success?
So thanks for the question, Joe. So on the compliance and adherence, I can't give you any sort of specifics to Altus. And what we see with the other long actions in the market is there is increased, as you imagine, compliance and adherence. You go from having a daily pill or multiple pills to have an injection once a month on your side case once every two months, then obviously, compliance and adherence increases pretty significantly. So we think that is a benefit, obviously, for the patients on the realizing that efficacy. But obviously, the continuation of therapy. And by the way, compliance with adherence, I'm sure you know is really important in schizophrenia because every relapse you have actually damages the brain. So the effectiveness of the medication after that starts to slightly go down. So you want to avoid anything. So compliance with adherent are key, which is why when you have a product like you said, but it's easy to use, easy to administer, no loading dose, just to bid levels within 24 hours, it gets you significantly because they want our patients to comply. And we see the same opportunity for three or so I don't have any details that maybe we'll look into that and see if we can find some data set, but it seems to be very clear from what we've seen with yes. Thank you for that question. Now moving on to CAC in the pipeline. I'll offer that one to talk a bit about that and our approach to that.
Yes. And thanks for the question on CLECs it's a broader question on FDA endpoints and speed to market. our teams take advantage of all possible ways of speeding things up. I know there's been a lot of change in the biosimilar space that we were a part of the conversation very early on, and we've been a part of the conversation with accelerating normal Phase III programs where we use one to two fatal trials. We always look at every option depending on the science tells us. The disease, we're moving very quickly in that space with the data that we've generated recently. -- our proof of concept. So that's driving our conversation on how to design our Phase II and our Phase III. And we're getting a little bit more of that next week. But we certainly have really honed in on what we're going to think those CBEC design studies are going to be. At the same time, we're moving very quickly into I, which is a very clear endpoint and pathway to registration. Thanks for your question.
Elliot, excuse me, I just kept to apologize, we have time only for one more question, but we can follow up with the sell-side analysts afterwards as we discussed before. So please stay tuned, and we can take any additional questions after the call. So we could have our last question, please, Elliot.
Of course, our last question comes from Chris Schott with JPMorgan.
Maybe just a two parter around how we're thinking about investments going forward. I when we look at R&D programs like the T-slip IL-13 or maybe any other broader immunology type programs you'd look at. Would you look to partner these like you did with the TL1A or do you feel like these are assets that Teva can now move forward on their own given the broader kind of footprint, investment opportunity, et cetera, that you have on the branded side? And maybe just a second part to that, I know you said a futility with Enroll Solan. Would you take another bet like that of kind of a high risk, high return asset? Or has the BD shift also move towards more derisked assets given the evolution of the company?
Thanks, Chris. Thanks for the question. So on TS13, the way we think about it, and you will hear a bit more of this next week at the R&D day is pretty simple. I would be fine science that works well prosecuted aggressively and quickly, and we'll work out the money on the way to speak. But what does that mean is we stay respectful of our commitment to increase shareholder value and to be respectful of margins. But at the same time, because of where we start from a gross margin point of view, we have more flexibility than most companies. And so that's how we think about it. Do we need to find the financial with? We'll see as that plays out. We'll see how many indications that could go, we'll see how many people want to be proud of that, whether that's financing or other companies. I think that just shows the optionalities we have at Teva to deal with products, which are multiple indications and exciting areas. So that's one. On the second part, which is on the.
Yes. Does that stop us going after those maybe no probability of success as it going forward?
Yes. I suppose it's a simple answer to that. And then the question was probably, well, why did you do this one? Well, when can I came together back in 2023, we looked at it and can actually the ability to actually get to this point we have today, require very little capital. We actually understood the size pretty well actually, this could have a chance unlesbecause of that, we actually went forward and did it. So the capital allocation was a big part of it. We didn't have to, there was no opportunity cost for doing this one, so to speak. Going forward, we don't see the need to do that. We want to focus on things which have a higher probability of success. That is our R&D strategy. That is our BD strategy. And that's how we think we can consistently give good returns to our investors over a long period of time, by really been talking about capital allocation and risk. Thanks, Chris. Thanks for your question. And I think that's the last question. So I want to thank everybody for that. interest in Teva and the continued interest in Teva. And I look forward to meeting many of you in New York at the R&D Day next week. Thanks very much.
Thank you, everyone. Thank you, Elliot.
Ladies and gentlemen, today's call has now concluded. We'd like to thank you for your participation. You may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teva Pharmaceutical Industries Limited transcript - plus 261,000+ transcripts from 13,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Teva Pharmaceutical Industries Limited earnings transcripts and 261,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $145 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.